The US Food and Drug Administration has cleared two new blood tests for Alzheimer’s disease in less than a week. This is another major step toward making the disease easier to assess without invasive procedures. The latest clearance went to Roche for its Elecsys pTau217 test on Monday, just four days after the agency cleared C2N Diagnostics‘ PrecivityAD2.
Researchers have been racing to make Alzheimer’s diagnosis faster and more accessible, particularly as new treatments make earlier identification of the disease more important.
Roche test targets Alzheimer’s-related brain changes
One of the tests cleared by the FDA is the Elecsys pTau217 test. BY: ROCHE DIAGNOSTICS
Roche announced Monday, August 24, that the FDA had cleared its Elecsys Phospho-Tau (217P) Plasma, or pTau217, blood test for people 55 and older who have signs, symptoms, or complaints of cognitive decline. Developed in collaboration with Eli Lilly, the test measures a single biomarker, phosphorylated tau 217, to help determine whether a patient is likely to have amyloid pathology associated with Alzheimer’s disease.
Roche said the test can produce positive, intermediate, or negative results and is intended to help doctors decide whether additional evaluation, including PET imaging or cerebrospinal fluid testing, may be appropriate.
President and CEO of Roche Diagnostics, Dan Malarek, per the above source, said: “Elecsys® pTau217 has the potential to transform how Alzheimer’s is assessed across primary and specialty care. This kind of innovation can help bring diagnostic evaluation closer to patients and give clinicians greater confidence in determining the right step in their care.”
The test is designed to run on more than 4,500 Roche laboratory analyzers already installed in US laboratories, making it easier for health systems to adopt the technology.
Second test cleared just days earlier
PrecivityAD2 can even detect Alzheimer’s disease symptoms in younger people too. BY: NIH SEED
The FDA cleared C2N Diagnostics’ PrecivityAD2 on August 20, making it the third FDA-cleared blood-based biomarker test for Alzheimer’s at the time. It is also the first FDA-cleared Alzheimer’s blood test indicated for adults as young as 40 who have signs or symptoms of cognitive impairment. PrecivityAD2 uses multiple biomarkers and an algorithm to help determine whether amyloid pathology associated with Alzheimer’s is present.
C2N says the test is designed to aid health care professionals in ruling in or ruling out clinical Alzheimer’s disease alongside a standard clinical evaluation. FDA clearance is a major milestone because blood-based testing has been gaining momentum as an alternative to more expensive methods for assessing amyloid plaques.
Blood tests could reduce need for scans and spinal taps
Blood tests have become increasingly effective in detecting the disease. BY: MY DIAGNOSTICS
For years, doctors have relied heavily on PET scans and cerebrospinal fluid testing when they need to determine whether Alzheimer’s-related amyloid pathology is present. Those approaches can be expensive and difficult to access. A blood draw is much simpler and could allow more patients to undergo biomarker testing earlier in the diagnostic process.
The FDA cleared the first blood test for aiding Alzheimer’s diagnosis in May 2025. Fujirebio’s Lumipulse test measures pTau217 and beta-amyloid 1-42 and was cleared for adults 55 and older with signs and symptoms of the disease. The Alzheimer’s Association said the C2N clearance was the third blood-based biomarker test cleared by the FDA, while Roche’s clearance on August 24 brought the total to four.
Experts caution that tests are not standalone diagnoses
Other ways like scans can also prove helpful. BY: THE TELEGRAPH
Despite the rapid progress, the new tests are not intended to replace a doctor’s overall evaluation. Roche specifically says Elecsys pTau217 should not be used as a standalone diagnostic test. Results need to be considered alongside clinical information and other relevant findings.
The FDA has also previously warned that false-positive and false-negative results from blood-based Alzheimer’s tests can have consequences. Still, the arrival of two additional tests in the same week highlights how quickly Alzheimer’s diagnostics are changing.